1-2 of 2
Eva González-Barca
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4762–4770.
https://doi.org/10.1182/bloodadvances.2021004619
Published: 2021
Includes: Supplemental data
Journal Articles

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Clinical Trials & Observations
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trněný
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1283–1290.
https://doi.org/10.1182/bloodadvances.2020002690
Published: 2021
Includes: Supplemental data